Other

Debt Instrument, Unamortized Discount And Debt Issuance Costs, Net

CVS Health Debt Instrument, Unamortized Discount And Debt Issuance Costs, Net decreased by 1.4% to $638.00M in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 12.2%, from $727.00M to $638.00M. Over 2 years (FY 2022 to FY 2024), Debt Instrument, Unamortized Discount And Debt Issuance Costs, Net shows relatively stable performance with a -3.6% CAGR.

Analysis

StatementBalance Sheet Statement
SectionOther
First reportedQ4 2022
Last reportedQ3 2025
Metric ID: other_debt_instrument_unamortized_discount_and_debt_issu_f23f33

Historical Data

7 periods
 Q4 '22Q3 '23Q4 '23Q2 '24Q3 '24Q4 '24Q3 '25
Value$696.00M$755.00M$736.00M$748.00M$727.00M$647.00M$638.00M
QoQ Change—+8.5%-2.5%+1.6%-2.8%-11.0%-1.4%
YoY Change——+5.7%—-3.7%-12.1%-12.2%
Range$638.00M – $755.00M
CAGR-5.6%
Avg YoY Growth-5.6%
Median YoY Growth-7.9%
Current Streak3 quarters decline

Frequently Asked Questions

What is CVS Health's debt instrument, unamortized discount and debt issuance costs, net?
CVS Health (CVS) reported debt instrument, unamortized discount and debt issuance costs, net of $638.00M in Q3 2025.
How has CVS Health's debt instrument, unamortized discount and debt issuance costs, net changed year-over-year?
CVS Health's debt instrument, unamortized discount and debt issuance costs, net decreased by 12.2% year-over-year, from $727.00M to $638.00M.
What is the long-term trend for CVS Health's debt instrument, unamortized discount and debt issuance costs, net?
Over 2 years (2022 to 2024), CVS Health's debt instrument, unamortized discount and debt issuance costs, net has grown at a -3.6% compound annual growth rate (CAGR), from $696.00M to $647.00M.